Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03704818 · ClinicalTrials.gov registry record · Phase 1
Dapagliflozin Effects on Hypoglycemia
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03704818 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 22 participants.
The verdict
NCT03704818, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this research study will be to test and evaluate if dapagliflozin has an effect on the amount of glucagon (a hormone produced by the pancreas and stomach that stimulates liver glucose production) produced by the body and if that change will improve recovery time from hypoglycemia (low blood sugar) in participants with Type 1 Diabetes.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Dapagliflozin 5mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-10-08 |
| Est. Completion | 2021-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03704818
The ClinicalTrials.gov registry entry for NCT03704818 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03704818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03704818 about?
NCT03704818 is a clinical study titled "Dapagliflozin Effects on Hypoglycemia". The purpose of this research study will be to test and evaluate if dapagliflozin has an effect on the amount of glucagon (a hormone produced by the pancreas and stomach that stimulates liver glucose production) produced by the body and if that change will improve recovery time from hypoglycemia (low...
What is the current status of trial NCT03704818?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-10-08. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT03704818?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Dapagliflozin 5mg (DRUG).
Who is sponsoring clinical trial NCT03704818?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.